MetaVia Taps AI Platform To Uncover New Disease Targets For Vanoglipel, Syntekabio Collaboration Highlights Inflammation, Cancer Potential For MetaVia’s Lead Drug

MetaVia Inc. shared progress from its collaboration with AI-driven drug discovery firm Syntekabio, highlighting how the partnership is shaping the future development strategy for its lead oral GPR119 agonist, vanoglipel (DA-1241). The companies are using Syntekabio’s proprietary DeepMatcher® platform to analyze compound-protein interactions and uncover new therapeutic opportunities.

Through this AI-based modeling, Syntekabio identified several high-value disease areas where vanoglipel could have potential benefit, including inflammatory conditions, cardiometabolic disorders, and cancer. The cancer signal was linked in part to predicted pathways associated with strong anti-inflammatory effects, reinforcing MetaVia’s interest in broader immune-metabolic applications.

"The AI modeling results provide strong confirmation that vanoglipel engages key inflammatory targets, which supports our strategy in metabolic dysfunction-associated steatohepatitis (MASH) and potential type 2 diabetes (T2D)," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "Furthermore, the identification of inflammation, cardiometabolic, and cancer-related pathways reinforces that we are focused in the right therapeutic areas. MetaVia continues to advance DA-1241 for MASH and T2D, bolstered by our Phase 2a clinical study results which demonstrated direct hepatic activity, improvements in glucose metabolism, and a favorable safety and tolerability profile in 109 patients over 16 weeks. Together, these insights give us confidence in DA-1241's broader therapeutic potential."

MetaVia said the findings closely align with its core mission of addressing cardiometabolic disease and open the door to additional future indications. The company plans to continue working with Syntekabio to refine vanoglipel’s therapeutic profile and assess its suitability across a wider range of diseases.